Weight-Loss drug semaglutide tested as cannabis craving cure
NCT ID NCT07523633
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether semaglutide (Wegovy), a drug used for weight loss, can help adults with cannabis use disorder use less cannabis. 100 participants will receive either semaglutide or a placebo injection weekly for 20 weeks. The main goal is to see if the drug reduces total cannabis use compared to placebo, with brain scans in some participants to explore how it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (Wegovy)
What this could lead to
If it works, this could offer a new medication to help people cut down or stop cannabis use, addressing a condition with few approved treatments.
What could go wrong
This is an early Phase 2 trial with only 100 people, so results may not apply broadly. Semaglutide can cause nausea, vomiting, and other side effects, and the placebo group may also improve.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANNABIS USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Psychiatric Center Copenhagen, Frederiksberg Hospital
RECRUITINGFrederiksberg, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••